<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726399</url>
  </required_header>
  <id_info>
    <org_study_id>15-301</org_study_id>
    <nct_id>NCT02726399</nct_id>
  </id_info>
  <brief_title>Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer</brief_title>
  <official_title>Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare any good and bad effects of using ramucirumab along&#xD;
      with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual rate&#xD;
  </why_stopped>
  <start_date type="Actual">March 18, 2016</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">February 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>as measured from the start of the ramucirumab and trastuzumab to the date of either documentation of disease progression on chemotherapy with trastuzumab and ramucirumab or death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days</description>
    <arm_group_label>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days</description>
    <arm_group_label>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period</description>
    <arm_group_label>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80mg/m2 administered as an IV infusion every 21 days</description>
    <arm_group_label>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have pathologically or cytologically MSKCC confirmed diagnosis of&#xD;
             gastric or GEJ adenocarcinoma.&#xD;
&#xD;
          -  Patients must have Stage IV gastric or GEJ adenocarcinoma with HER2 overexpression&#xD;
             and/or amplification as determined by next generation sequencing assay,&#xD;
             immunohistochemistry (IHC 3+) or fluorescent in situ hybridization (FISH+ is defined&#xD;
             as HER2:CEP17 ratio ≥ 2.0). MSKCC confirmation of HER2 status is not mandatory prior&#xD;
             to enrollment and treatment on study. For patients with outside HER2 testing, if&#xD;
             sufficient tissue is available HER2 testing will be repeated at MSKCC for purpose of&#xD;
             analysis and will not impact the patient's eligibility.&#xD;
&#xD;
          -  Available archival tumor tissue should be submitted to MSKCC for IMPACT analysis, but&#xD;
             will not be required prior to registration. Note: if tissue is depleted, patient will&#xD;
             still be eligible after discussion with the PI.&#xD;
&#xD;
          -  Patients must have disease that can be evaluated radiographically. This may be&#xD;
             measurable disease or non-measurable disease per RECIST 1.1.&#xD;
&#xD;
          -  Patients may have received no prior chemotherapy for Stage IV disease. Patients may&#xD;
             have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than&#xD;
             6 months have elapsed between the end of adjuvant therapy and registration.&#xD;
&#xD;
          -  Age of 18 years or older.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Peripheral neuropathy ≤ grade 1&#xD;
&#xD;
          -  Patients who have adequate hepatic function as defined by a total bilirubin ≤1.5 times&#xD;
             upper limit of institutional normal value (ULN) mg/dL (except patients with Gilbert's&#xD;
             disease), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times&#xD;
             ULN or ≤ 5.0 times the ULN in the setting of liver metastases.&#xD;
&#xD;
          -  Patients who have adequate hematologic function, as evidenced by absolute neutrophil&#xD;
             count (ANC) ≥1500/μL, hemoglobin ≥9 g/dL (5.58 mmol/L), and platelets ≥100,000/μL.&#xD;
&#xD;
          -  Patients who have adequate renal function as defined by calculated creatinine&#xD;
             clearance ≥60 mL/minute using the Cockcroft-Gaul formula or equivalent method.&#xD;
&#xD;
          -  Patients whose urinary protein is ≤2+ on routine urinalysis (UA; if routine analysis&#xD;
             is &gt;2+, a 24-hour urine collection for protein must demonstrate &lt;2g of protein in 24&#xD;
             hours to allow participation in this protocol).&#xD;
&#xD;
          -  The patient must have adequate coagulation function as defined by International&#xD;
             Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds&#xD;
             above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin&#xD;
             must be switched to low molecular weight heparin and have achieved stable coagulation&#xD;
             profile prior to first dose of protocol therapy.&#xD;
&#xD;
          -  Patients, must be postmenopausal, surgically sterile, or using effective contraception&#xD;
             (hormonal or barrier methods).&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 7 days of study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have uncontrolled or poorly-controlled hypertension (&gt;160 mmHg systolic&#xD;
             or &gt;100 mmHg diastolic for &gt;4 weeks) despite standard medical management.&#xD;
&#xD;
          -  Patients receiving any concurrent anticancer therapy or investigational agents with&#xD;
             the intention of treating gastric/GEJ cancer. Previously received trastuzumab as part&#xD;
             of a regimen in the metastatic setting with evidence of progression. 89Zr-trastuzumab&#xD;
             use as imaging agent for 89Zr-trastuzumab PET permitted.&#xD;
&#xD;
          -  Patients having:&#xD;
&#xD;
               -  Cirrhosis at a level of Child-Pugh B (or worse) or&#xD;
&#xD;
               -  Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically&#xD;
                  meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is&#xD;
                  defined as ascites from cirrhosis requiring diuretics or paracentesis.&#xD;
&#xD;
          -  Active or clinically significant cardiac disease including:&#xD;
&#xD;
               -  Congestive heart failure - New York Heart Association (NYHA) &gt; Class II.&#xD;
&#xD;
               -  Active coronary artery disease.&#xD;
&#xD;
               -  Left ventricular function &lt;50%.&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or&#xD;
                  digoxin.&#xD;
&#xD;
               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months&#xD;
                  before randomization, or myocardial infarction within 6 months before&#xD;
                  randomization.&#xD;
&#xD;
               -  Patients who have experienced any arterial thromboembolic events, including but&#xD;
                  not limited to myocardial infarction, transient ischemic attack, cerebrovascular&#xD;
                  accident, or unstable angina, within 6 months prior to enrollment.&#xD;
&#xD;
               -  Patients who are receiving chronic antiplatelet therapy, including aspirin,&#xD;
                  nonsteroidal anti-infalmmatory drugs (NSAIDs, inluding ibuprofen, naproxen, and&#xD;
                  others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin&#xD;
                  (maximum dose 325 mg/day is permitted.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Patients who have experienced any Grade 3-4 GI bleeding within 3 months prior to&#xD;
             enrolment.&#xD;
&#xD;
          -  Unwillingness to give written informed consent, unwillingness to participate, or&#xD;
             inability to comply with the protocol for the duration of the study.&#xD;
&#xD;
          -  Patients with prior trastuzumab treatment.&#xD;
&#xD;
          -  Patients with known active brain or central nervous system metastases, including&#xD;
             leptomeningeal disease. Patients with treated and asymptomatic brain metastases may be&#xD;
             eligible after discussion with PI.&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  The patient has undergone major surgery within 28 days prior to first dose of protocol&#xD;
             therapy&#xD;
&#xD;
          -  Patients may not have had major surgical procedure within 2 weeks of registration.&#xD;
&#xD;
          -  Patients who have elective or planned major surgery to be performed during the course&#xD;
             of the clinical trial.Minor surgery/subcutaneous venous access device placement within&#xD;
             7 days prior to first dose of protocol therapy is permitted.&#xD;
&#xD;
          -  Patients may not have had radiation within 28 days prior to first dose weeks of&#xD;
             registration.&#xD;
&#xD;
          -  Patients may not have any other medical condition or reason, in that investigator's&#xD;
             opinion, makes the patient unstable to participate in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yelena Janjigian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center 1275 York Avenue</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <results_first_submitted>December 19, 2019</results_first_submitted>
  <results_first_submitted_qc>December 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2020</results_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ramucirumab</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>HER2-Positive</keyword>
  <keyword>15-301</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02726399/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</title>
          <description>This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.&#xD;
Ramucirumab: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days&#xD;
Trastuzumab: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days&#xD;
Capecitabine: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period&#xD;
Cisplatin: Cisplatin 80mg/m2 administered as an IV infusion every 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</title>
          <description>This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.&#xD;
Ramucirumab: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days&#xD;
Trastuzumab: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days&#xD;
Capecitabine: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period&#xD;
Cisplatin: Cisplatin 80mg/m2 administered as an IV infusion every 21 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>as measured from the start of the ramucirumab and trastuzumab to the date of either documentation of disease progression on chemotherapy with trastuzumab and ramucirumab or death.</description>
        <time_frame>6 months</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</title>
            <description>This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.&#xD;
Ramucirumab: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days&#xD;
Trastuzumab: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days&#xD;
Capecitabine: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period&#xD;
Cisplatin: Cisplatin 80mg/m2 administered as an IV infusion every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>as measured from the start of the ramucirumab and trastuzumab to the date of either documentation of disease progression on chemotherapy with trastuzumab and ramucirumab or death.</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Data were not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Ramucirumab With Trastuzumab and Capecitabine/Cisplatin</title>
          <description>This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.&#xD;
Ramucirumab: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days&#xD;
Trastuzumab: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days&#xD;
Capecitabine: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period&#xD;
Cisplatin: Cisplatin 80mg/m2 administered as an IV infusion every 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yelena Janjigian, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4186</phone>
      <email>janjigiy@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

